Servier

GeNeuro is a clinical-stage biotechnology company based in Plan-Les-Ouates, Switzerland, specializing in the development of therapeutic drugs for diseases linked to the expression of pathogenic proteins derived from human endogenous retroviruses. The company primarily targets nervous system disorders, including multiple sclerosis and schizophrenia. Its lead product, GNbAC1, is a therapeutic monoclonal antibody aimed at treating multiple sclerosis, while temelimab, another candidate, neutralizes a pathogenic protein associated with the HERV-W family. In addition to its therapeutic developments, GeNeuro also focuses on creating diagnostic tests to measure multiple sclerosis-associated retrovirus-ENV proteins in patients. Founded in 2006, GeNeuro is committed to addressing the underlying causes of neurodegenerative and autoimmune diseases.

Agios Pharmaceuticals is a biopharmaceutical company focused on developing targeted therapies in the field of cellular metabolism. It discovers and develops medicines for various indications, including hematologic malignancies, solid tumors, and rare genetic diseases.

Symphogen specializes in the development of recombinant polyclonal antibodies (rpAbs), a novel biopharmaceutical class. The company focuses on creating treatments and prophylactics for severe human diseases, with a particular emphasis on cancer and infectious diseases. Their pipeline includes rpAb compositions for treating idiopathic thrombocytopenic purpura, preventing hemolytic disease in newborns, and mitigating adverse reactions from smallpox vaccinations, aiming to facilitate faster cancer treatment initiation and enhance overall treatment success.